Home
Storia in 3 fonti
Regeneron immunotherapy combo comes up short in melanoma trial
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.
- ·
biopharmadive.com
Regeneron immunotherapy combo comes up short in melanoma trial
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out…
- ·
benzinga.com
Why Is Regeneron Stock Sinking Monday? - Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
- ·
endpoints.news
Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3
Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class.